The global, first-in-human, open-label trial will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TRI-611
The collaboration highlights the rising importance of intranasal delivery in developing non-vaccine approaches to respiratory disease prevention
Targets diabetes & obesity crisis as India grapples with soaring metabolic disorders
The once-weekly treatment targets Type 2 Diabetes Mellitus (T2DM) with demonstrated efficacy and safety
The patent protects antiviral compounds developed by the company that inhibit Vacuolar ATPase (V-ATPase) activity in cells, a mechanism involved in viral infection pathways
India’s largest glycolic acid manufacturer will unveil AviGa Bio HP70 on April 14, 2026
The initiative will be led by David Baker, 2024 Nobel Prize winner in Chemistry, IPD director, professor of biochemistry, and HHMI Investigator at the University of Washington
Both companies say the collaboration is driven by a shared mission to improve patient outcomes by aligning every step of the diagnostic process
KeyCi’s dermatologically tested lineup emphasizes clean formulations—vegan, cruelty-free, alcohol-free, and paraben-free—while being backed by pharmaceutical-grade research and FDA approval
These approvals represent a defining moment for people living with classical Hodgkin Lymphoma
Subscribe To Our Newsletter & Stay Updated
